Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
710 (USA) · Dr. Silva
consented 2012-12-26
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-28 (study day 34.0); relationship: POSSIBLE
moderate
assessed
Moderate PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-01-28 (study day 34.0); relationship: POSSIBLE
moderate
assessed
Moderate RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-28 (study day 34.0); relationship: POSSIBLE
moderate
assessed
Moderate RASH — outcome: RECOVERED/RESOLVED; onset 2013-01-28 (study day 34.0); relationship: POSSIBLE
Data queries
No data queries.